Tau protein as a potential predictive marker in epithelial ovarian cancer patients treated with paclitaxel/platinum first-line chemotherapy

Journal of Experimental and Clinical Cancer Research

Volumn 32, Issue 1, 2013, Pages

  Smoter, Marta ^a   Bodnar, Lubomir ^a   Grala, Bartlomiej ^a   Stec, Rafal ^a   Zieniuk, Krystyna ^a   Kozlowski, Wojciech ^a   Szczylik, Cezary ^a  

^a MILITARY INSTITUTE OF MEDICINE   (Poland)

Author keywords

Chemotherapy; Ovarian cancer; Predictive factor; Prognostic factor; Tau protein

Indexed keywords

CARBOPLATIN; CISPLATIN; FORMALDEHYDE; PACLITAXEL; PARAFFIN; TAU PROTEIN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; CHEMOSENSITIVITY; CLINICAL EVALUATION; CORRELATIONAL STUDY; CYTOREDUCTIVE SURGERY; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVARY CARCINOMA; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; GENE EXPRESSION; HUMANS; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PACLITAXEL; PLATINUM; PROGNOSIS; TAU PROTEINS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84876786400     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-32-25     Document Type: Article

References (19)

1. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. McGuire WP, Hoskins WJ, Brady MF, N Engl J Med 1996 334 1 6 10.1056/NEJM199601043340101 7494563 (Pubitemid 26012496)
2. Randomized intergroup trial of cisplatin- paclitaxel versus cisplatin- cyclophosphamide in women with advanced epithelial ovarian cancer: three year results. Piccart M, Bertrlsen K, James K, J Natl Cancer Inst 2000 92 699 708 10.1093/jnci/92.9.699 10793106 (Pubitemid 30365530)
3. How Taxol stabilises microtubule structure. Amos LA, Löwe J, Chem Biol 1999 6 65 9 10.1016/S1074-5521(99)89002-4 (Pubitemid 29363146)
4. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Rouzier R, Rajan R, Wagner P, Proc Natl Acad Sci USA 2005 102 8315 20 10.1073/pnas.0408974102 15914550 (Pubitemid 40800086)
5. Repeat motifs of tau bind to the insides of microtubules in the absence of taxol. Kar S, Fan J, Smith MJ, Goedert M, Amos LA, EMBO J 2003 22 70 77 10.1093/emboj/cdg001 12505985 (Pubitemid 36091270)
6. Taxol- induced Flexibility of Microtubules and Its reversal by MAP-2 and Tau. Dye RB, Fink SP, Williams RC, J Biol Chem 1993 268 6847 6850 8096507 (Pubitemid 23105559)
7. Tau and taupathies. Robert M, Mathuranath PS, Neurol India 2007 55 11 16 10.4103/0028-3886.30420 17272893
8. Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial. Pusztai L, Jeong JH, Gong Y, J Clin Oncol 2009 27 4287 92 10.1200/JCO.2008.21. 6887 19667268
9. Reduced tau expression in gastric cancer can identify candidates for successful Paclitaxel treatment. Mimori K, Sadanaga N, Yoshikawa Y, Br J Cancer 2006 94 1894 7 10.1038/sj.bjc.6603182 16721363 (Pubitemid 43882581)
10. Tau expression and efficacy of paclitaxel treatment in metastatic breast cancer. Tanaka S, Nohara T, Iwamoto M, Cancer Chemother Pharmacol 2009 64 341 6 10.1007/s00280-008-0877-5 19039589
11. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial. Pentheroudakis G, Kalogeras KT, Wirtz RM, Breast Cancer Res Treat 2009 116 131 43 10.1007/s10549-008-0144-9 18668363
12. Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response. Rody A, Karn T, Gätje R, Breast 2007 16 86 93 10.1016/j.breast.2006.06.008 17010609 (Pubitemid 46172862)
13. Paclitaxel and carboplatin as neoadjuvant chemotherapy in patients with locally advanced breast cancer: a phase II trial of the Hellenic cooperative oncology group. Gogas H, Pectasides D, Kostopoulos I, Clin Breast Cancer 2010 10 230 7 10.3816/CBC.2010.n.031 20497922
14. Meta-analysis of gene expression profiles associated with histological classification and survival in 829 ovarian cancer samples. Fekete T, Rásó E, Pete I, Int J Cancer 2012 131 95 105 10.1002/ijc.26364 21858809
15. Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin. Shao YY, Kuo KT, Hu FC, Jpn J Clin Oncol 2010 40 286 93 10.1093/jjco/hyp184 20085902
16. Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy. Han LY, Karavasilis V, Hagen T, Eur J Cancer 2010 46 1359 64 10.1016/j.ejca.2010.02.012 20303743
17. Prognostic factors of secondary cytoreductive surgery for patients with recurrent epithelial ovarian cancer. Bae J, Lim MC, Choi JH, J Gynecol Oncol. 2009 20 101 6 10.3802/jgo.2009.20.2.101 19590721
18. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Chi DS, McCaughty K, Diaz JP, Cancer 2006 106 1933 9 10.1002/cncr.21845 16572412 (Pubitemid 43673208)
19. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. International Collaborative Ovarian Neoplasm Group, Lancet 2002 360 505 15 12241653